Info

Nabi Biopharmaceuticals is a biopharmaceutical company focused on the development of products in the areas of nicotine addiction and infectious disease. The Company’s products in development are Nicotine Conjugate Vaccine (NicVAX) and Staphylococcus aureus Vaccine (StaphVAX). On December 4, 2007, the Company sold its biologics business to Biotest. In May 2007, the Company sold certain assets related to Aloprim to Bioniche Teoranta. In July 2007, the Company created the second of its strategic business units (SBU), Nabi Pharmaceuticals. Nabi Pharmaceuticals is responsible for the NicVAX and StaphVAX development programs. In December 2007, the Company sold its assets related to Biologics SBU (Nabi Biologics) to Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG.